About us

Altevax was co-founded by Victor Vadaneaux and Prof. Antoine Carpentier to exploit a patent family filed by Assistance Publique - Hôpitaux de Paris (“APHP”) and Université Paris XIII, and of which Prof. Carpentier is the inventor and author.

Altevax also secured the backing of Agoranov, the leading incubator of the city of Paris.

Victor Vadaneaux, CEO, has a vast business experience managing companies and also as a private equity investor. An Ecole Polytechnique graduate and holder of an MBA from Harvard, Victor started working at Roussel Uclaf, a pharmaceutical company now part of Sanofi. He worked with McKinsey & Co and had a private equity career at GE Capital and Advent International, where he was a Partner. He then became an entrepreneur backed by institutional investors, building a business which he later sold. Victor is an Operating Partner with private equity firms helping build value in their portfolio businesses.

Professor Antoine Carpentier, inventor of the melanin-based vaccine technology, is a neuro oncologist, Head of the Neurology Department of the Saint Louis Hospital in Paris, part of APHP. He has been the primary investigator of 14 neuro-oncology clinical trials and author/co-author of more than 100 international scientific publications.

Contact

Victor Vadaneaux, President
victor.vadaneaux@altevax.com
+33 9 70 40 54 00

Altevax SAS
55 Avenue Marceau - 75116 Paris
France
© Copyright Altevax 2018 - All Rights Reserved
Mentions légales : Site et contenus propriétés d'Altevax
Création et intégration : Justine Gélis / Justincreations.fr
Hébergeur OVH